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Abstract
Introduction. There are several published clinical trials of the use of tranexamic
acid (TXA) in an obstetric setting, but no consensus on its use or guidelines for
management. Material and methods. The aim of this meta-analysis was to evalu-
ate the effectiveness of TXA in reducing blood loss when given prior to cesarean
delivery. We performed a systematic search in electronic databases. We included
all randomized controlled trials comparing the use of TXA prior to cesarean
delivery with controls (either placebo or no treatment). Results. Nine trials with
2365 women were included in the analysis. Women who received TXA had sig-
nificantly less postpartum blood loss, a lower drop in hemoglobin and a lower
incidence of postpartum hemorrhage and severe postpartum hemorrhage com-
pared with controls. Moreover, the number of women who needed additional
uterotonic agents was significantly lower in the TXA group than in controls.
The percentage of women who required blood transfusions at, or immediately
after, cesareans was significantly lower in the intervention group than in the
controls. There was no difference in the incidence of thromboembolic events in
the two groups. Conclusions. Prophylactic TXA given before cesarean skin inci-
sion in women undergoing cesarean delivery, under spinal or epidural anesthe-
sia, significantly decreases blood loss, including postpartum hemorrhage and
severe postpartum hemorrhage, in addition to the standard prophylactic oxy-
tocin given after delivery of the neonate. The effect of TXA on thromboembolic
events and mortality as well as its use in high-risk women should be investi-
gated further.
Abbreviations: CD, cesarean delivery; CI, confidence interval; PPH, postpartum
hemorrhage; RCT, randomized controlled trials; RR, relative risk; TXA,
tranexamic acid.
Introduction
The World Health Organization defines postpartum hem-
orrhage (PPH) as “blood loss from the birth canal in
excess of 500 mL during the first 24 h after delivery” (1),
Key Message
Prophylactic tranexamic acid given before cesarean
skin incision significantly decreases blood loss.
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although currently there is a debate about what definition
to use (2).
Postpartum hemorrhage is responsible for about 25%
of maternal deaths worldwide (1), and 12% of survivors
will have severe anemia (1). Clinically, it is associated
with weakness, sweating, and tachycardia, and with
hemodynamic collapse occurring at losses of between 35
and 45% of blood volume (3). One of the most common
complications of cesarean delivery (CD) is PPH, which
can be life-threatening. Recently, CD rates have increased
to as high as 25–35% in many areas of the developed
world (4).
Antifibrinolytic agents, mainly tranexamic acid (TXA),
have been demonstrated to reduce blood loss and the
need for transfusion requirements in various non-obste-
tric surgeries (5–8). There are several published clinical
trials for the use of TXA in the obstetric setting as well
(9–16), but no consensus on its use or guidelines for
management. Moreover, no meta-analysis evaluated
specifically the efficacy of TXA given prophylactically at
the time of CD to reduce blood loss.
The aim of this meta-analysis of randomized controlled
trials (RCTs) was to evaluate the effectiveness of TXA
given prior to CD to reduce blood loss in women under-
going CD.
Material and methods
The research protocol was designed a priori, defining
methods for searching the literature, including and exam-
ining articles, and extracting and analyzing data. Searches
were performed in MEDLINE, OVID, Scopus, ClinicalTri-
als.gov, the PROSPERO International Prospective Register
of Systematic Reviews, EMBASE and the Cochrane Cen-
tral Register of Controlled Trials with the use of a combi-
nation of the following text words: “cesarean”,
“postpartum hemorrhage”, “caesarean”, “randomized”
and “tranexamic acid”, from the inception of each data-
base to August 2015. No restrictions in language or geo-
graphic location were applied. The articles, including
their references, were initially scanned by two authors
(G.S., M.B.) based on titles and abstracts.
We included all RCTs comparing the use of TXA prior
to CD with controls (either placebo or no treatment).
Quasi-randomized trials (trials in which allocation was
done on the basis of a pseudo-random sequence, e.g.
odd/even hospital number or date of birth, alternation)
were excluded. Eligibility criteria were limited to intra-
venous TXA given prior to CD. Before data extraction,
the review was registered with the PROSPERO Interna-
tional Prospective Register of Systematic Reviews (regis-
tration No. CRD42014014826). The meta-analysis was
reported following the Preferred Reporting Item for Sys-
tematic Reviews and Meta-analyses (PRISMA) statement
(17).
Database searching and data abstraction was completed
by two independent investigators (G.S., M.B.). Each
investigator independently abstracted data from each
study separately onto custom-made data collection forms.
Differences were reviewed and further resolved by com-
mon review of the entire data. All authors were contacted
for missing data.
The risk of bias in each included study was assessed
using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (18). Seven domains
145 records
identified through
database
searching
123 records after duplicates
removed
9 studies included
in qualitative
synthesis
and in the
meta-analysis
123 records 
screened
114 records 
excluded (no
randomized
controlled trials)
9 full-text articles
assessed for
eligibility
Figure 1. Flow diagram of studies identified in the systematic review.
Prisma template (Preferred Reporting Item for Systematic Reviews and
Meta-analyses).
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related to risk of bias were assessed in each included trial
since there is evidence that these issues are associated
with biased estimates of treatment effect: (i) random
sequence generation; (ii) allocation concealment; (iii)
blinding of participants and personnel; (iv) blinding of
outcome assessment; (v) incomplete outcome data; (vi)
selective reporting; and (vii) other bias. Review authors’
judgments were categorized as “low risk”, “high risk” or
“unclear risk” of bias (18).
All analyses were done using an intention-to-treat
approach, evaluating women according to the treatment
group to which they were randomly allocated in the
original trials. The primary outcome was postpartum
blood loss, defined as the amount of blood loss (mL) in
case of cesarean section, as defined in the trial. Second-
ary outcomes included incidence of PPH (i.e. blood loss
more than 500 mL), severe PPH (i.e. blood loss more
than 1000 mL), use of additional medical interventions
to control PPH, thromboembolic events, hemoglobin
and hematocrit drop 24 h after CD, blood transfusions
at or immediately after cesarean, severe maternal mor-
bidity (e.g. intensive care unit admission, hysterectomy,
organ failure) and maternal adverse drug reactions. We
planned a subgroup analysis using only placebo-con-
trolled trials.
The data analysis was completed independently by
authors (G.S., M.B.) using REVIEW MANAGER 5.3
(Copenhagen: The Nordic Cochrane Centre, Cochrane
Collaboration, 2014). The completed analyses were then
compared and any difference was resolved by review of
the entire data and independent analysis. Statistical
heterogeneity between studies was assessed using the Hig-
gins I2 statistic. In case of statistically significant hetero-
geneity (I2 ≥50%) the random effect model of
DerSimonian and Laird was used to obtain the pooled
risk estimate, otherwise a fixed effect model was used.
The summary measures were reported as relative risk
(RR) or mean difference with 95% confidence interval
(CI). Potential publication biases were assessed statisti-
cally using Begg’s and Egger’s tests. A p-value <0.05 was
considered statistically significant.
Results
Nine RCTs which met inclusion criteria for this meta-
analysis were analyzed (9–16,19). Figure 1 shows the flow
Random sequence generation (selection bias)
(b)(a)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
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diagram (PRISMA template) of information through the
different phases of the review. The quality of RCTs
included in our meta-analysis was assessed by the
Cochrane Collaboration’s tool (Figure 2). Most of the
included studies had low risk of bias in “random
sequence generation” and all of them had low risk of bias
in “incomplete outcome data”. All trials were rated as
low risk of bias for selective outcome reporting and the
overall risk of bias was low. Publication bias, assessed
using Begg’s and Egger’s tests, showed no significant bias
(p = 0.61 and p = 0.51, respectively).
Table 1 shows the characteristics of the included RCTs.
Six studies used placebo as control. Of the 2365 women
undergoing CD under spinal or epidural anesthesia
included in the analysis, 1193 (50%) were randomized to
TXA groups and 1172 (50%) to control. Six studies
included only singleton gestations (9,11–14,16). Two stud-
ies included only women who planned to have a scheduled
CD at ≥37 weeks (12,16). All studies used I g TXA (or
10 or 15 mg/kg) i.v. 10–20 min before skin incision or
spinal anesthesia as intervention. One study enrolled two
random intervention groups (10 and 15 mg/kg) (19). All
included studies used oxytocin standard prophylaxis, usu-
ally after delivery of the neonate or, in two studies (11,15),
after delivery of the placenta, in both intervention and con-
trol groups. Blood loss was measured as described in
Table 1 in the different studies. The Indian RCT enrolled
90 women with anemia defined by authors as hemoglobin
between 7 and 10 g/dL (19), while the rest of the RCT par-
ticipants were low-risk women undergoing CD under
spinal or epidural anesthesia.
Women who received TXA had a statistically significant
lower postpartum blood loss (mean difference –160.27 mL,
95% CI 224.63 to 95.92) compared with women who
did not receive it (Figure 3). The statistical heterogeneity
within the studies was high (I2 = 97%) and therefore
the random effect model of DerSimonian and Laird was
utilized to obtain the pooled risk estimates for all out-
comes.
Table 2 shows the pooled results for secondary out-
comes. Women who were randomized to TXA had a
significantly lower incidence of PPH, i.e. blood loss
more than 500 mL (9.4 vs. 44.5%; RR 0.21, 95% CI
0.16–0.28), and of severe PPH, i.e. blood loss more than
1000 mL (1.2 vs. 2.9%; RR 0.42, 95% CI 0.19–0.92),
compared with controls. The number of women who
needed additional uterotonic agents was statistically sig-
nificantly lower in the TXA than in the control group
(4.2 vs. 7.3%; RR 0.54, 95%CI 0.36–0.81). Women who
received TXA had a statistically significantly lower
hemoglobin drop 24 h after CD compared with controls
(mean difference 0.61 g/dL, 95% CI 1.04 to 0.18).
The percentage of women who required blood transfu-
sions at or immediately after cesarean was significantly
lower in the intervention group than in the control
group (1.9 vs. 5.7%; RR 0.33, 95% CI 0.19–0.58). No
significant differences were found in the hematocrit drop
(mean difference 0.66%, 95% CI 2.32 to 1.00). All
studies specifically reported thromboembolic events.
However, no cases of thromboembolic events in either
group was found, except for one study (12) which
reported four women who experienced thromboembolic
events, two in the intervention and two in the placebo
group [2/1133 (0.18%) vs. 2/1142 (0.17%); RR 0.98,
95% CI 0.13–7.09]. No maternal severe morbidity or
adverse drug reactions were reported in either group (9–
16).
In the sensitivity analysis of only placebo-controlled tri-
als, women who received TXA had a statistically signifi-
cantly lower postpartum blood loss (mean difference
136.75 mL, 95% CI 217.39 to 56.11; Figure 4), sev-
ere PPH (1.8 vs. 5.3%; RR 0.37, 95% CI 0.16–0.86),
blood transfusion (2.1 vs. 6.3%; RR 0.33, 95% CI 0.19–
0.58) and had a significantly lower hemoglobin drop
(mean difference 0.19 g/dL, 95% CI 0.26 to 0.12)
but a higher hematocrit drop 24 h after CD (mean differ-
ence 0.21%, 95% CI 0.15–0.28) compared with women
who did not. Moreover, the number of women who
Study or subgroup
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needed additional uterotonic agents was statistically sig-
nificantly lower in the TXA than the control group (8.5
vs. 15.6%; RR 0.53, 95% CI 0.36–0.80). No significant
difference was found in the incidence of PPH comparing
TXA with controls (7.9 vs. 12.8%; RR 0.62, 95% CI 0.25–
1.53) (Table 3).
Discussion
This meta-analysis of the nine RCTs evaluating the effi-
cacy of prophylactic TXA in reducing postpartum blood
loss at CD shows that TXA is associated with a significant
decrease in postpartum blood loss, a significantly lower
incidence of PPH and severe PPH, a significantly lower
hemoglobin drop, and significantly less need for addi-
tional uterotonic agents with two controls (either placebo
or no treatment).
Another meta-analysis, published as a Cochrane
Review, evaluated the efficacy of TXA in reducing post-
partum blood loss (20). It showed that TXA decreases
postpartum blood loss. However it included studies both
on vaginal birth and on CD and did not include a
recent RCT (16). Faraoni et al. and Heesen et al. pub-
lished meta-analyses evaluating the prophylactic efficacy
of TXA in women at low risk for post-partum haemor-
rhage (21,22). Both showed TXA reduces port-partum
blood loss. Unfortunately, these two meta-analyses did
not include all currently available RCTs on cesarean,
had therefore smaller numbers, and included vaginal
delivery trials, too (21,22). This is the first meta-analysis
specifically evaluating the efficacy of TXA given prophy-
lactically at time of CD to reduce blood loss.
TXA is a lysine analogue which acts as an antifibrinolytic
via competitive inhibition of the binding of plasmin and
plasminogen to fibrin (23). Peak plasma TXA concen-
tration is obtained immediately after intravenous adminis-
tration, then concentration decreases until the 6th h. Its
half-life is about 2 h (23). It has been studied extensively in
non-pregnant adults (5–8,24,25). A Cochrane review
showed that TXA significantly reduces blood transfusion in
patients undergoing emergency or urgent non-obstetrical
surgery (24). TXA is safe in pregnancy, being FDA category
B. One concern regarding use of TXA in pregnancy is the
potential for thromboembolic events in a population at
already high baseline risk of thrombosis (26). This should
be kept in mind when considering use of TXA. However,
our analysis showed no significant difference in incidence
of thromboembolic events comparing TXA with the con-
trol groups.
Our study has several strengths. The included studies
were of high quality and with a low risk of bias according
to the Cochrane risk of bias tools. Other strengths are the
inclusion of only randomized trials, of only patients with
cesarean delivery, and of similar dosing used in the trials.
To our knowledge, no prior meta-analysis on the issue of
TXA in obstetrics is as large, up-to-date or comprehen-
sive. Moreover, we studied a specific population, only
women having a cesarean delivery, as incidences of blood
loss complications are different in this population com-
pared to women delivering vaginally. Additionally, while
most of the included studies primarily reported on post-
partum blood loss, we further analyzed PPH, severe PPH,
and need for additional uterotonics. All trials reported
results regarding safety data, i.e. risk for thrombotic
events and no increased risk was noticed.
Limitations of our study are inherent to the limitations
of the included RCTs. While blood transfusion was signif-
icantly less in the TXA group, the transfusion policy was
specified only in two studies (11,13). Movafegh and col-
leagues transfused at a hemoglobin level below 7 g/dL,
while Xu et al. below 8 g/dL. No cost-effectiveness analy-
sis was assessed. In 5 studies (9–11,15,16), data were
reported regarding neonate effects, and no increased risk
was noticed. Nonetheless, TXA has not been reported to
have effects on the neonate, and is FDA category B. In
some of the included trials, the prevalence of reported
complications in the placebo arm appeared excessively
high. Movafegh et al. reported separately data regarding
mean intraoperative blood loss (262  39 mL vs.
404  94 mL) and regarding mean postoperative blood
Study or subgroup
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loss (67  6.5 mL vs. 141  34 mL); we reported the
added means in the primary analysis but calculating the
standard deviations was not feasible, and so this study
was excluded from the primary analysis (Figures 3 and
4). Goswani et al. reported separately data regarding
mean blood loss in the two intervention groups
(256.83  102.946 and 159.0  68.143) and so calculat-
ing the primary outcome for the all women enrolled in
the intervention arm was not feasible.
In summary, the addition of TXA to the standard oxy-
tocin prophylaxis at CD is associated with significant
decreases in all of the following: postpartum blood loss,
PPH and severe PPH, need for additional uterotonic
agents, hemoglobin drop, and need for blood transfusion.
Therefore, given its benefit in preventing one of the most
common and serious complications of pregnancy, as well
as its safety and now proven effectiveness in pregnancy,
we suggest consideration for adding tranexamic acid, 1 g
(or 10 mg/kg) i.v. 10–20 min before skin incision or
spinal anesthesia, to oxytocin prophylaxis given after
delivery of the neonate, as prophylaxis to further reduce
of blood loss at cesarean delivery. This should be in par-
ticular for cases at risk for complications from PPH, such
as women with prior PPH, anemia, grandmultiparity,
infection, Jehovah’s witnesses, etc. However, given the
lack of safety data, large and well-designed placebo-con-
trolled trials are needed. Trials in selected women (e.g.
women already anemic before cesarean delivery) are also
required.
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